| Sonstiges: |
- Nachgewiesen in: USPTO Patent Grants
- Sprachen: English
- Patent Number: 7,662,820
- Publication Date: February 16, 2010
- Appl. No: 11/981398
- Application Filed: October 30, 2007
- Assignees: SanRX Pharmaceuticals, Inc. (La Jolla, CA, US)
- Claim: 1. The compound dipterinyl calcium pentahydrate (DCP).
- Claim: 2. A method of synthesizing dipterinyl calcium pentahydrate (DCP) comprising: dissolving pterin in an aqueous solution of NaOH, adding CaCl 2 .2H 2 O to the solution with stirring at a pH of about 11, continuing stirring for about 1 day, and collecting the precipitate as DCP.
- Claim: 3. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound dipterinyl calcium pentahydrate (DCP).
- Current U.S. Class: 514/249
- Patent References Cited: 6358953 March 2002 Moheno ; 6844343 January 2005 Pfleiderer et al.
- Other References: Mitsumi, et al., Molecular Crystals & Liquid Crystals Science & Technology, Section A: Molecular Crystals & Liquid Crystals (1996), 276, 229-235. cited by examiner ; Cameron, D.A. et al., “Tamoxifen induced apoptosisin ZR-75 breast cancer xenografts antedates tumour regression,” Breast Cancer Res. Treat. 45(20:99-107 (1997). cited by other ; Emi, M. et al., “Targeted therapy against Bc1-2-related proteins in breast cancer cells,” Breast Cancer Res. 7(6):R940-R952 (2005). cited by other ; Han, G.Z. et al., “Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer,” Cancer Res. 65(2):387-393 (2005). cited by other ; Hoke, E.M. et al., “Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin,” Free Radic. Biol. Med. 39(3):403-411 (2005). cited by other ; Jones, L.W., “Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts,” Clin. Cancer Res. 11(18):6695-6698 (2005). cited by other ; Jordan, V.C. et al., “Immune-deficient animals to study “hormone-dependent” breast and endometrial cancer,” J. Steroid Biochem. 34(1-6):169-176 (1989). cited by other ; Kokolis et al., “Pteridine and Riboflavin in Tumor Tissue and the Effect of Chloramphenicol and Isoxanthopterin,” Z. Naturforsch. B27:292-295 (1972). cited by other ; LaMontagne, K.R. et al., “Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models,” Mol. Cancer Ther. 5(2):347-355 (2006). cited by other ; Lewisohn et al., “The Action of Xanthopterin on Tumor Growth,” Proc. Soc. Exp. Biol. Med. 56:144-145 (1944). cited by other ; Liao, Y. et al., “Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer,” Cancer Gene Ther. 11(9):594-602 (2004). cited by other ; Mewani, R.R. et al., “Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models,” Int. J. Oncol. 24(5):1181-1188 (2004). cited by other ; Milacic, V. et al., “A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts,” Cancer Res. 66(21):10478-10486 (2006). cited by other ; Robinson, S.P. et al., “Preclinical studies with toremifene as an antitumor agent,” Breast Cancer Res. Treat. 16 (Suppl):S9-S17 (1990). cited by other ; Robinson, S.P. et al., “Antiestrogenic action of toremifene on hormone-dependent,—independent, and heterogeneous breast tumor growth in the athymic mouse,” Cancer Res. 49(7):1758-1762 (1989). cited by other ; Sweeney, C.J. et al., “The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer,” Mol. Cancer Ther. 4(6):1004-1012 (2005). cited by other ; Taras, T.L., et al., “In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer,” J. Steroid Biochem. Mol. Biol. 77(4-5):271-279 (2001). cited by other ; Warnberg, F. et al., “Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo,” Breast Cancer Res. 8(2):R21-R31 (2006), Epub Apr. 12, 2006. cited by other ; Winkler et al., “Calcium-pterin suppresses mitogen-induced tryptophan degradation and neopterin production in peripheral blood mononuclear cells,” Immunobiology 211:779-784 (2006). cited by other ; Woessner, R. et al., “Comparison of three approaches todoxorubicin therapy: free doxorubicin, liposomal doxorubicin, and beta-glucuronidase-activated prodrug (HMR 1826),” Anticancer Res. 20(4):2289-2296 (2000). cited by other ; Yamamoto, D. et al., “Synergistic effects induced by cycloprodigiosin hydrochloride and epirubicin on human breast cancer cells,” Breast Cancer Res. Treat. 72(10):1-10 (2002). cited by other ; Yen, W.C. et al., “The selective retinoid X receptor agonistbexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma,” Mol. Cancer Ther. 4(5):824-834 (2005). cited by other ; Crispini, A. et al., “Hdrogen-bonding network in metal-pterin complexes: Synthesis and characterization of water-soluble octahedral nickel and cadmium pterine derivatives,” Crystal Growth & Design 5(4):1597-1601 (2005). cited by other ; Mitsumi, M. et al., “Metal-pteridine complexes having three-dimensional hydrogen-bonded networks,” Inorg. Chem. 34(12):3367-3370 (1995). cited by other ; PCT/US07/23012 Search Report dated Jun. 17, 2008. cited by other ; Moheno, P., et al., “Plasma Cytokine Changes Induced by the Antitumor Agents Dipterinyl Calcium Pentahydrate (DCP) and Related Calcium Pterins,” Immunology, article in press, received Apr. 2, 2008. cited by other ; Moheno, P., et al., “Plasma Cytokine Changes Induced by the Antitumor Agents Dipterinyl Calcium Pentahydrate (DCP) and Related Calcium Pterins,” Pteridines 19 (2):49 (2008). cited by other ; Moheno, P., et al., “Cytokine and IDO Metabolite Changes Effected by Calcium Pterin During Inhibition of MDA-MB-231 Xenograph Tumors in Nude Mice,” International Journal of Pharmaceutics 355:238-248 (2008). cited by other ; Moheno, P., et al., “Mechanism of Action Studies with the Antitumor Agent Calcium-Pterin,” Pteridines 18(2):50 (2007). cited by other ; Moheno, P., et al., “Role of Calcium Pterin in Natural Killer (NK) Cell Activation and Indoleamine 2,3-Dioxygenase (IDO) Modulation for Antitumor Activity,” Pteridines 16:140 (2005). cited by other ; Moheno, P., et al., “Calcium Pterin as an Antitumor Agent,” International Journal of Pharmaceutics 271:293-300 (2004). cited by other ; Winkler, C., et al., “Calcium-Pterin Suppresses Mitogen-Induced Tryptophan Degradation and Neopterin Production in Peripheral Blood Mononuclear Cells,” Immunobiology 211:779-784 (2006). cited by other ; Stea, B., et al., “Folate and Pterin Metabolism by Cancer Cells in Culture,” Cancer Research 38:2378-2384 (1978). cited by other
- Assistant Examiner: Jaisle, Cecilia M
- Primary Examiner: Berch, Mark L
- Attorney, Agent or Firm: Wilson Sonsini Goodrich & Rosati
|
